Erlotinib Online


Buy Tarceva (Erlotinib HCl) anticancer medication
Cheap qualitative Erlotinib 150 mg tablets online



HOW AND WHERE TO BUY ERLOTINIB HCL (TARCEVA) 150 MG TABLETS ONLINE:


CHEAP MEDS FOR SALE

Lowest prices
Good quality
from $34.30 per pill
5% discount coupon: 5OFF



DISCOUNT MEDS

Low prices
High quality
from $38.17 per pill
5% discount coupon: dmeds5



MEDICINES STORE

Average prices
Best quality
from $45.50 per pill
5% discount coupon: MSD5




TARCEVA (ERLOTINIB): CLINICAL STUDIES

NSCLC - Maintenance Study

The efficacy and safety of Tarceva (Erlotinib Hydrochloride) as maintenance treatment of NSCLC were demonstrated in a randomized, double-blind, placebo-controlled trial conducted in 26 countries, in 889 patients with locally advanced or metastatic NSCLC whose disease did not progress during first line platinum-based chemotherapy. Patients were randomized 1:1 to receive Erlotinib Hydrochloride (Tarceva) 150 mg or placebo orally once daily (438 Tarceva, 451 placebo) until disease progression or unacceptable toxicity. The primary objective of the study was to determine if the administration of Tarceva (Erlotinib HCl) after standard platinum-based chemotherapy in the treatment of NSCLC resulted in improved progression free survival (PFS) when compared with placebo, in all patients or in patients with EGFR immunohistochemistry (IHC) positive tumors.

The PFS and OS Hazard Ratios, respectively, in patients with EGFR IHC-positive tumors were 0.69 (95% CI: 0.58, 0.82) and 0.77 (95% CI: 0.64, 0.93). The PFS and OS Hazard Ratios in patients with IHC-negative tumors were 0.77 (95% CI: 0.51, 1.14) and 0.91 (95% CI: 0.59, 1.38), respectively.

Patients with adenocarcinoma had an OS Hazard Ratio of 0.77 (95% CI: 0.61, 0.97) and patients with squamous histology had an OS Hazard Ratio of 0.86 (95% CI: 0.68, 1.10).

NSCLC - Second / Third Line Study

The efficacy and safety of single-agent Erlotinib HCl (Tarceva) was assessed in a randomized, double blind, placebo-controlled trial in 731 patients with locally advanced or metastatic NSCLC after failure of at least one chemotherapy regimen. Patients were randomized 2:1 to receive Tarceva (Erlotinib HCl) tablets 150 mg or placebo (488 Tarceva, 243 placebo) orally once daily until disease progression or unacceptable toxicity. Study endpoints included overall survival, response rate, and progression-free survival (PFS). Duration of response was also examined. The primary endpoint was survival. The study was conducted in 17 countries.

Survival was evaluated in the intent-to-treat population.

NSCLC - Tarceva Administered Concurrently with Chemotherapy

Results from two, multicenter, placebo-controlled, randomized, trials in over 1000 patients conducted in first-line patients with locally advanced or metastatic NSCLC showed no clinical benefit with the concurrent administration of Erlotinib HCl (Tarceva) tablets with platinum-based chemotherapy [carboplatin and paclitaxel (Tarceva, N = 526) or gemcitabine and cisplatin (Tarceva, N = 580)].

Pancreatic Cancer - Tarceva Administered Concurrently with Gemcitabine

The efficacy and safety of Tarceva tablets in combination with gemcitabine as a first-line treatment was assessed in a randomized, double blind, placebo-controlled trial in 569 patients with locally advanced, unresectable or metastatic pancreatic cancer. Patients were randomized 1:1 to receive Tarceva (100 mg or 150 mg) or placebo once daily on a continuous schedule plus gemcitabine IV (1000 mg/m2, Cycle 1 - Days 1, 8, 15, 22, 29, 36 and 43 of an 8 week cycle; Cycle 2 and subsequent cycles - Days 1, 8 and 15 of a 4 week cycle [the approved dose and schedule for pancreatic cancer, see the gemcitabine package insert]). Erlotinib tablets or placebo was taken orally once daily until disease progression or unacceptable toxicity. The primary endpoint was survival. Secondary endpoints included response rate, and progression-free survival (PFS). Duration of response was also examined. The study was conducted in 18 countries. A total of 285 patients were randomized to receive gemcitabine plus Tarceva (261 patients in the 100 mg cohort and 24 patients in the 150 mg cohort) and 284 patients were randomized to receive gemcitabine plus placebo (260 patients in the 100 mg cohort and 24 patients in the 150 mg cohort). Too few patients were treated in the 150 mg cohort to draw conclusions.

Survival was evaluated in the intent-to-treat population. Figure 3 depicts the Kaplan-Meier curves for overall survival in the 100 mg cohort. The primary survival and PFS analyses were two-sided Log-Rank tests stratified by ECOG performance status and extent of disease.

Recent posts:

  • Buy Tarceva (Erlotinib) Online
  • Tarceva prescribing information

    Copyright © Buy Erlotinib Online